Germline pathogenic variants in BRCA1, BRCA2, PALB2 and RAD51C in breast cancer women from Argentina.

Roxana CerretiniGraciela MercadoJosh MorgansteinJorge SchiaffiMónica ReynosoDiana MontoyaRita ValdézSteven A NarodMohammadreza Akbari

Published in: Breast cancer research and treatment (2019)

A founder mutation in PALB2 accounts for up to 4% of breast cancer patients in Argentina. BRCA1, BRCA2, PALB2 and RAD51C should be included in the genetic testing panel of breast cancer patients in Argentina.

Keyphrases

breast cancer risk
dna repair
dna damage
polycystic ovary syndrome
copy number
pregnant women
gene expression
adipose tissue
genome wide